Compass Therapeutics, Inc. financial data

Symbol
CMPX on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 05 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1199% % -45%
Debt-to-equity 15% % 110%
Return On Equity -44% % -25%
Return On Assets -38% % -17%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 180,087,915 shares 30%
Common Stock, Shares, Outstanding 178,324,000 shares 29%
Entity Public Float $277,000,000 USD 183%
Common Stock, Value, Issued $18,000 USD 29%
Weighted Average Number of Shares Outstanding, Basic 157,695,000 shares 15%
Weighted Average Number of Shares Outstanding, Diluted 137,600,000 shares

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $55,969,000 USD 32%
General and Administrative Expense $16,870,000 USD 11%
Operating Income (Loss) $72,839,000 USD -29%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $16,633,000 USD -54%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $66,489,000 USD -35%
Earnings Per Share, Basic -0.42 USD/shares -17%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $30,643,000 USD -30%
Marketable Securities, Current $178,263,000 USD 114%
Assets, Current $209,819,000 USD 58%
Property, Plant and Equipment, Net $102,000 USD -71%
Operating Lease, Right-of-Use Asset $9,099,000 USD 35%
Other Assets, Noncurrent $568,000 USD 78%
Assets $219,588,000 USD 56%
Accounts Payable, Current $1,585,000 USD -30%
Accrued Liabilities, Current $11,383,000 USD 81%
Liabilities, Current $13,968,000 USD 57%
Operating Lease, Liability, Noncurrent $8,829,000 USD 40%
Liabilities $22,797,000 USD 50%
Accumulated Other Comprehensive Income (Loss), Net of Tax $280,000 USD 33%
Retained Earnings (Accumulated Deficit) $431,172,000 USD -18%
Stockholders' Equity Attributable to Parent $196,791,000 USD 57%
Liabilities and Equity $219,588,000 USD 56%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $13,208,000 USD 4.9%
Net Cash Provided by (Used in) Financing Activities $815,000 USD -105%
Net Cash Provided by (Used in) Investing Activities $11,588,000 USD
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 178,324,000 shares 29%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,435,000 USD -340%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $31,211,000 USD -29%
Deferred Tax Assets, Gross $81,808,000 USD 33%
Operating Lease, Liability $9,829,000 USD 43%
Depreciation $100,000 USD -50%
Payments to Acquire Property, Plant, and Equipment $18,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $66,419,000 USD -35%
Lessee, Operating Lease, Liability, to be Paid $11,623,000 USD 36%
Property, Plant and Equipment, Gross $6,739,000 USD 0.37%
Operating Lease, Liability, Current $1,000,000 USD 196%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,204,000 USD 117%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,525,000 USD 108%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1,794,000 USD 6.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three $2,249,000 USD 59%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $2,294,000 USD 59%
Operating Lease, Payments $1,300,000 USD 0%
Deferred Tax Assets, Net of Valuation Allowance $2,563,000 USD 35%
Share-based Payment Arrangement, Expense $8,368,000 USD -2.2%